Leaflet RENEOS 0.5mg tablets

Product code:
W56718002
Quantity:
90
Indicated for:
type 2 diabetes mellitus
Route of administration:
oral
Substance:
repaglinide (antidiabetic)
ATC
A10BX02 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Other blood glucose lowering drugs, excl. insulins

Precautions:

Hypoglycemia

Hypoglycemia

This medicine may lower blood sugar.

Repaglinide is a medication used to control blood sugar levels in patients with type 2 diabetes. It stimulates the pancreas to release insulin, thereby helping to lower blood sugar levels after meals.

The medication is taken orally, usually before meals, and should be used as directed by your doctor. It is important to follow the recommended diet and exercise regimen to achieve the best results.

Side effects may include hypoglycemia (low blood sugar), nausea, diarrhea, or weight gain. In rare cases, severe allergic reactions or other complications may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as liver or kidney diseases, to ensure the safe use of repaglinide.

General data about RENEOS 0.5mg

Substance:
repaglinide
Date of latest medicines list:
01-06-2026
Product code:
W56718002
Concentration:
0.5mg
Pharmaceutical form:
tablets
Quantity:
90
Product type:
Generic medicine
Price:
35.83 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
DELORBIS PHARMACEUTICALS LTD. - CIPRU
Holder:
ZENTIVA, K.S. - REPUBLICA CEHA
Number:
8505/2016/02
Shelf life:
3 years

Pharmaceutical forms available for repaglinide

Concentrations available for repaglinide

  • 0.5mg
  • 1mg
  • 2mg
  • 4mg

Compensation lists for RENEOS 0.5mg Zentiva

NHP 5 (C2) - Diabetes

Price
35.83 RON
Copayment
17.18 RON
Patient
18.65 RON